Anand Rathi is bullish on Pfizer India has recommended buy rating on the stock with a target price of Rs 4800 in its research report dated February 10, 2023.

Hold Pfizer; target of Rs 4505: ICICI Direct

ICICI Direct recommended hold rating on Pfizer with a target price of Rs 4505 in its research report dated November 17, 2022.

Hold Pfizer; target of Rs 4480: ICICI Direct

ICICI Direct recommended hold rating on Pfizer with a target price of Rs 4480 in its research report dated August 06, 2022.

Buy Pfizer; target of Rs 4810: ICICI Direct

ICICI Direct recommended hold rating on Pfizer with a target price of Rs 4810 in its research report dated May 23, 2022.

Hold Pfizer: target of Rs 6690: ICICI Direct

ICICI Direct recommended hold rating on Pfizer with a target price of Rs 6690 in its research report dated July 29, 2021.

Buy Pfizer India; target of Rs 5655: Anand Rathi

Anand Rathi is bullish on Pfizer India has recommended buy rating on the stock with a target price of Rs 5655 in its research report dated February 08, 2021.

Buy Pfizer; target of Rs 5890: ICICI Direct

ICICI Direct is bullish on Pfizer has recommended buy rating on the stock with a target price of Rs 5890 in its research report dated November 02, 2020.

Buy Pfizer; target of Rs 4740: ICICI Direct

ICICI Direct is bullish on Pfizer recommended buy rating on the stock with a target price of Rs 4740 in its research report dated July 07, 2020.

Buy Pfizer; target of Rs 4705: ICICI Securities

ICICI Securities is bullish on Pfizer recommended buy rating on the stock with a target price of Rs 4705 in its research report dated June 15, 2020.

Buy Pfizer; target of Rs 3100: Centrum

Centrum recommended hold rating on Pfizer with a target price of Rs 3100 in its research report dated September 10, 2018.

Buy Pfizer; target of Rs 3000: ICICI Direct

ICICI Direct is bullish on Pfizer has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated May 08, 2018.

Buy Pfizer; target of Rs 2300: Centrum

Centrum is bullish on Pfizer has recommended buy rating on the stock with a target price of Rs 2300 in its research report dated November 17, 2017.

Hold Pfizer; target of Rs 2010: Centrum

Centrum recommended hold rating on Pfizer with a target price of Rs 2010 in its research report dated November 07, 2016.

Buy Pfizer; target of Rs 2425: ICICIdirect

ICICIdirect.com has recommended to buy Pfizer in the range of Rs 2100-2050 for a target of Rs 2425 with a stop loss below Rs 1940 on a closing basis, in its research report dated March 09, 2015.

Buy Pfizer; target of Rs 1270: Firstcall Research

Brokerage house Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target price of Rs 1270 in its research report dated March 04, 2014.

Buy Pfizer; target Rs 1720: Firstcall Research

Brokerage house Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target price of Rs 1720 in its November 26, 2013 research report.

Buy Pfizer; target Rs 1107: Firstcall Research

Brokerage house Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target price of Rs 1107 in its August 28, 2013 research report.

Buy UltraTech, Madras Cements, Pfizer, Mcleod: AnandRathi

AnandRathi Securities has recommended to buy UltraTech Cement, Pfizer, Madras Cements and Mcleod Russel India with a target price of Rs 2100, Rs 215, Rs 1232 and Rs 400 respectively, in its research report dated July 30, 2013.

Buy Pfizer; target of Rs 1300: Firstcall Research

Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target of Rs 1300 in its December 07, 2012 research report.

Accumulate Pfizer; target of Rs 1265: Emkay

Emkay Global Financial Services is bullish on Pfizer and has recommended accumulate rating on the stock with a target of Rs 1265 in its August 16, 2012 research report.

Buy Pfizer; target of Rs 1339: Firstcall Research

Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target of Rs 1339 in its December 7, 2011 research report.

Accumulate Pfizer; target of Rs 1417: Emkay

Emkay Global Financial Services is bullish on Pfizer and has recommended accumulate rating on the stock with a target of Rs 1417 in its May 4, 2011 research report.

Accumulate Pfizer; target of Rs 1193: Emkay

Emkay Global Financial Services is bullish on Pfizer and has recommended accumulate rating on the stock with a target of Rs 1193 in its January 12, 2011 research report.